The QuantideX® NGS DNA Hotspot 21 Kit (RUO) is a next generation sequencing (NGS) research tool that interrogates 46 hotspot regions (amplicons) within 21 genes that are commonly mutated in a number of solid and hematological malignancies. The kit detects over 1,500 known variants, including single nucleotide variants (SNVs), insertions/deletions (indels), and structural rearrangements. Leveraging our proprietary NGS-in-a-Box™ workflow and Sample-Aware™ bioinformatics quality control solutions, this kit provides a simple, robust, and reliable NGS assay for the routine investigation of these genomic variants.
The QuantideX NGS DNA Hotspot 21 Kit combines Asuragen’s unique NGS-in-a-Box™ solution with a streamlined testing workflow to enable unprecedented NGS workflow efficiency and high sensitivity at low input amounts from precious FFPE samples.
Reduced ComplexityAssay incorporates sample-to-data solutions in a unique NGS-in-a-Box™ configuration
Optimized WorkflowProvides operational efficiencies to reduce testing costs, hands-on and total turnaround time
Quality PerformanceHighly sensitive assay with integrated, Sample-Aware™ bioinformatics software and built-in quality checks to minimize erroneous results and sample failures
Relevant ContentThe QuantideX NGS DNA Hotspot 21 Kit detects over 1,500 genomic variants as reported in the Catalogue of Somatic Mutations in Cancer (COSMIC) Database within 21 genes, representing approximately 80% of known variants within these targets.
Table 1: Mutation coverage of QuantideX NGS DNA Hotspot 21 Kit
Table 2: Clinical relevance of covered mutations
1NCCN Clinical Practice Guidelines*Includes gastric, pancreatic, glicomas, sarcomas, and other tumor types
A Fully Integrated WorkflowA unique NGS-in-a-Box™ configuration offers a simplified and fully integrated NGS workflow with cGMP-manufactured reagents, components and controls ready to use.
Includes:
Rapid & EfficientAdopt and run NGS-based analysis with minimum investment of time and resources, regardless of NGS experience and infrastructure.
Performance Data
Highly Sensitive and Accurate Detection of DNA Mutations
Push-button analytics & reporting suite – Set-up-and-go workflow designed for easy installation and implementation, right out of the box.
Operates on a standard desktop computer – Install locally on a desktop computer using Windows® operating system. No prior bioinformatics experience or large server environments required.
Comprehensive– Full bioinformatics and reporting of variants (SNVs, Indels), and standard QC metrics are automatically calculated.
Integrates Sample-Aware™ – Bioinformatics with integrated functional template copy number analysis dramatically reduces false-call rates.
Next-Generation Sequencing Within Your Reach: Implementation of an Actionable Mutation Panel for Molecular Oncology Testing
Analytical Validation Of The QuantideX® NGS DNA Hotspot 21 Kit, A Diagnostic NGS System for the Detection of Actionable Mutations in FFPE TumorsView full poster
A Machine-Learning Framework for Accurate Classification and Quantification of Oncogenic Variants Using the QuantideX® NGS DNA Hotspot 21 KitView full poster
A Simple and Versatile Next-Generation Sequencing Technology for Co-Detection of RNA Structural Variants and DNA Mutations in Lung CancerView full poster
Product Name | Number of Reactions | Catalog Number |
---|---|---|
QuantideX NGS DNA Hotspot 21 Kit* | 48 | 46108 |
T 1.877.777.1874 | 512.681.5200 F 512.681.5202 E orders@asuragen.com
*For Research Use Only. Not for use in Diagnostic procedures.
The QuantideX® NGS DNA Hotspot 21 Kit is an in vitro diagnostic, next-generation sequencing (NGS) panel for the detection of clinically relevant variants across a multitude of tumor types, including non-small cell lung cancer, colorectal cancer, and melanoma. The kit screens for over 1,500 known genomic variants, including single nucleotide variants (SNVs), insertions/deletions (indels), and structural rearrangements, many of which are treatable with novel therapies, inform on patient management, or are the subject of further clinical evaluation. Leveraging our proprietary NGS-in-a-Box™ workflow and Sample-Aware™ bioinformatics quality control solutions, the panel provides a robust and reliable NGS solution for the identification of clinically relevant targets you and your clinicians can trust.
The QuantideX NGS DNA Hotspot 21 Kit combines Asuragen’s unique NGS-in-a-Box™ solution with a streamlined testing workflow to enable unprecedented NGS workflow efficiency and high sensitivity at low input amounts from precious FFPE samples.
Reduced ComplexityAssay incorporates sample-to-data solutions in a unique NGS-in-a-Box™ configuration
Optimized WorkflowProvides operational efficiencies to reduce testing costs, hands-on and total turnaround time
Quality PerformanceHighly sensitive assay with integrated, Sample-Aware™ bioinformatics software and built-in quality checks to minimize erroneous results and sample failures
Relevant ContentThe QuantideX NGS DNA Hotspot 21 Kit detects over 1,500 genomic variants as reported in the Catalogue of Somatic Mutations in Cancer (COSMIC) Database within 21 genes, representing approximately 80% of known variants within these targets. Several of these variants are associated with approved therapies, while others are currently in trials to clarify their clinical significance.
Table 1: Mutation coverage of QuantideX NGS DNA Hotspot 21 Kit
Table 2: Clinical relevance of covered mutations
1NCCN Clinical Practice Guidelines*Includes gastric, pancreatic, glicomas, sarcomas, and other tumor types
A Fully Integrated WorkflowA unique NGS-in-a-Box™ configuration offers a simplified and fully integrated NGS workflow with cGMP-manufactured reagents, components and controls ready to use.
Includes:
Rapid & EfficientAdopt and run NGS-based analysis with minimum investment of time and resources, regardless of NGS experience and infrastructure.
Performance Data
Push-button analytics & reporting suite – Set-up-and-go workflow designed for easy installation and implementation, right out of the box.
Operates on a standard desktop computer – Install locally on a desktop computer using Windows® operating system. No prior bioinformatics experience or large server environments required.
Comprehensive – Full bioinformatics and reporting of variants (SNVs, Indels) and standard QC metrics are automatically calculated.
Integrates Sample-Aware™ – bioinformatics with integrated functional template copy number analysis dramatically reduces false-call rates.
Next-Generation Sequencing Within Your Reach: Implementation of an Actionable Mutation Panel for Molecular Oncology Testing
Analytical Validation Of The QuantideX® NGS DNA Hotspot 21 Kit, A Diagnostic NGS System for the Detection of Actionable Mutations in FFPE TumorsView full poster
A Machine-Learning Framework for Accurate Classification and Quantification of Oncogenic Variants Using the QuantideX® NGS DNA Hotspot 21 KitView full poster
A Simple and Versatile Next-Generation Sequencing Technology for Co-Detection of RNA Structural Variants and DNA Mutations in Lung CancerView full poster
Product Name | Number of Reactions | Catalog Number |
---|---|---|
QuantideX NGS DNA Hotspot 21 Kit* | 48 | 76044 |
T 1.877.777.1874 | 512.681.5200 F 512.681.5202 E orders@asuragen.com
*For Research Use Only. Not for use in Diagnostic procedures.
asuragen的AmplideX®PCR / CE C9orf72试剂盒
C9orf72主网页图像小AmplideX PCR / CE C9orf72试剂盒(RUO)是用于检测C9orf72基因中GGGGCC重复序列的研究产品。这些试剂提供了基于重复引物PCR(RP-PCR)设计的单管PCR方法,以分析C9orf72基因中的重复序列 。
特点与优势
分析特性
订购方式
特点与优势
Asuragen已经建立了市场领先的技术,可以可靠地扩增和分析FMR1基因中CGG三联体重复序列。AmplideX PCR / CE C9orf72 试剂盒(RUO)是该技术向神经遗传学领域的扩展。该试剂盒为临床和药学研究人员提供了一种可靠且可重现的方法,可用于C9orf72基因中六核苷酸重复扩增的高分辨率基因分型 ,这对额颞叶痴呆(FTD)引起了越来越多的关注。疾病-肌萎缩性侧索硬化症(ALS)。
通过以下方法简化了 C9orf72基因的复杂度分析:
实施专有的二合一PCR解决方案以扩增富含GC的区域
单一来源的试剂盒,包含C9orf72 重复扩增所需的所有PCR试剂
简化的工作流程,动手时间最短
优化的工作流程
通过以下方式大大减少了宝贵的操作员动手时间:
单一PCR反应可用于上浆和筛选
直接将PCR产物注入(无需PCR清理)到毛细管电泳平台
减少对Southern blot分析的需求
质量绩效
执行C9orf72一个具有更高的灵敏度和准确度nalysis:
等位基因大小的长度提高了五倍:精确定量多达145个重复序列
检测到大于145个重复的等位基因
揭示低水平的镶嵌和次要等位基因